FONT-SIZE Plus   Neg

Delcath Says Hemofiltration Cartridge Gets CE Mark Approval

Oncology-based pharma and medical device company Delcath Systems, Inc. (DCTH) announced the receipt of CE Mark approval for the second-generation hemofiltration cartridge of its proprietary Hepatic CHEMOSAT Delivery System, allowing the company to now supply second-generation CHEMOSAT system to centers in Europe.

With the new hemofiltration cartridge, the company said, the CHEMOSAT system carries the same broad indication as the previous generation system, permitting physicians to use the product for the percutaneous intra-arterial administration of a chemotherapeutic agent to the liver to any patient who in their opinion may benefit.

"With the new hemofiltration cartridge, we believe that CHEMOSAT may help to improve the management of side effects on treated patients and potentially complement other systemic cancer therapies, leading to greater system utilization. We look forward to the first European commercial procedure using the new filter, which is scheduled for next week," Eamonn Hobbs, President & CEO of Delcath Systems said in a statement.

The approval from CE Mark allows Delcath to market and sell its Class III medical device in countries in the European Economic Area, or EEA. Delcath's new hemofiltration cartridge's design and technology is patent pending.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Consumer goods giant Procter & Gamble Co. on Tuesday reported a 4 percent increase in profit for the first quarter from last year on a slight decline in sales. However, both revenue and core earnings per share for the quarter beat analysts' estimates. In addition, the company affirmed its financial outlook for fiscal 2017. Merck & Co. Inc. (MRK) reported a profit for the third-quarter that increased about 20 percent, while quarterly worldwide sales grew 5 percent. The company raised its full-year 2016 outlook. Drug maker Eli Lilly and Co. reported Tuesday lower profit in its third quarter, despite higher revenues. Adjusted earnings per share and top line missed analysts' estimates. Further, for fiscal 2016, the company trimmed its forecast for reported earnings, while maintained adjusted earnings view, and raised revenue forecast.
comments powered by Disqus
Follow RTT